Adimmune Corporation (TPE:4142)

Taiwan · Delayed Price · Currency is TWD

18.50

-0.20 (-1.07%)

Apr 17, 2026, 1:30 PM CST

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Revenue from Internal Divisions			-27.03M	-119.03M	-22.00M	-	-
Antero Biotechnology			43.49M	188.42M	109.82M	-	-
Antero Biotechnology Growth			-76.92%	71.56%	-	-	-
Guoguang Biotechnology			1.77B	2.18B	1.71B	-	-
Guoguang Biotechnology Growth			-18.95%	27.92%	-	-	-
Pharmaceuticals			-	-	-	1.87B	1.30B
Pharmaceuticals Growth			-	-	-	43.81%	58.04%
Total			1.79B	2.25B	1.79B	1.87B	1.30B
Total Growth			-20.72%	25.52%	-4.03%	43.81%	58.04%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Taiwan			842.44M	959.02M	961.50M	1.29B	681.57M
Taiwan Growth			-12.16%	-0.26%	-25.58%	89.57%	50.96%
USA			326.82M	345.66M	456.18M	496.21M	-
USA Growth			-5.45%	-24.23%	-8.07%	-	-
China			477.56M	632.10M	183.88M	31.53M	-
China Growth			-24.45%	243.76%	483.13%	-	-
Other			138.28M	314.84M	192.21M	49.35M	618.12M
Other Growth			-56.08%	63.80%	289.45%	-92.02%	66.67%
Total			1.79B	2.25B	1.79B	1.87B	1.30B
Total Growth			-20.72%	25.52%	-4.03%	43.81%	58.04%

Source: S&P Global Market Intelligence.